IP
MLNT

Isthmus Partners’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Isthmus Partners’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-84,072
Closed -$7.66M – 210
2019
Q1 		$7.66M Buy
84,072
+81,072
+2,702% +$440K 1.86% 15
2018
Q4 		$12K Buy
+3,000
New +$38.4K ﹤0.01% 132

Other funds holding MLNT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Isthmus Partners's MLNT Position: Q2 2019 in Review

Isthmus Partners sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q2 2019, closing a stake of 84,072 shares — an estimated $7.66M sold.

Isthmus Partners first reported a position in MLNT in Q4 2018 and held it in 2 quarters. The position peaked at $7.66M in Q1 2019. 53 funds tracked by Wall St. Rank hold MLNT as of Q2 2019.

  • Isthmus Partners reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Isthmus Partners sold 84,072 Melinta Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $7.66M.
  • Isthmus Partners first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2018 and held it in 2 quarters.
  • Isthmus Partners's Melinta Therapeutics, Inc. Common Stock position peaked at $7.66M in Q1 2019.
  • 53 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Isthmus Partners's 13F filing for Q2 2019, filed 9 Aug 2019.